MXPA06001636A - Antagonista del receptor de la hormona concentradora de melanina. - Google Patents

Antagonista del receptor de la hormona concentradora de melanina.

Info

Publication number
MXPA06001636A
MXPA06001636A MXPA06001636A MXPA06001636A MXPA06001636A MX PA06001636 A MXPA06001636 A MX PA06001636A MX PA06001636 A MXPA06001636 A MX PA06001636A MX PA06001636 A MXPA06001636 A MX PA06001636A MX PA06001636 A MXPA06001636 A MX PA06001636A
Authority
MX
Mexico
Prior art keywords
group
methyl
tetrazol
phenyl
piperazine
Prior art date
Application number
MXPA06001636A
Other languages
English (en)
Spanish (es)
Inventor
Guity Balow
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MXPA06001636A publication Critical patent/MXPA06001636A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA06001636A 2003-08-13 2004-08-11 Antagonista del receptor de la hormona concentradora de melanina. MXPA06001636A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49473503P 2003-08-13 2003-08-13
PCT/US2004/026021 WO2005019167A2 (en) 2003-08-13 2004-08-11 Melanin concentrating hormone receptor antagonist

Publications (1)

Publication Number Publication Date
MXPA06001636A true MXPA06001636A (es) 2006-04-28

Family

ID=34215897

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06001636A MXPA06001636A (es) 2003-08-13 2004-08-11 Antagonista del receptor de la hormona concentradora de melanina.

Country Status (7)

Country Link
US (2) US7514438B2 (cg-RX-API-DMAC7.html)
EP (1) EP1653960A4 (cg-RX-API-DMAC7.html)
JP (1) JP2007502287A (cg-RX-API-DMAC7.html)
AU (1) AU2004266233A1 (cg-RX-API-DMAC7.html)
CA (1) CA2533112A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA06001636A (cg-RX-API-DMAC7.html)
WO (1) WO2005019167A2 (cg-RX-API-DMAC7.html)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1558582B1 (en) 2003-07-22 2005-12-21 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
PE20100809A1 (es) 2005-07-11 2011-01-07 Wyeth Llc Inhibidores de glutamato de metaloproteinasas de matriz y agrecanasas
GT200600414A (es) * 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine
AR055424A1 (es) * 2005-09-12 2007-08-22 Wyeth Corp Formulacion de liberacion sostenida y usos de la misma
GT200600416A (es) * 2005-09-12 2007-09-20 Sales salicilato y gentisato de un compuesto de piperazina
ATE429428T1 (de) 2005-09-30 2009-05-15 Hoffmann La Roche Indanderivate als antagonisten des mch-rezeptors
EP1934171A1 (en) 2005-10-13 2008-06-25 Wyeth a Corporation of the State of Delaware Methods for preparing glutamic acid derivatives
US20090018142A9 (en) * 2006-05-02 2009-01-15 Zhengping Zhuang Use of phosphatases to treat tumors overexpressing N-CoR
AU2007254179B2 (en) 2006-05-18 2013-03-21 Pharmacyclics Llc Intracellular kinase inhibitors
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物
WO2008086069A1 (en) * 2007-01-03 2008-07-17 The General Hospital Corporation Methods of treating itch
US7998957B2 (en) 2007-02-06 2011-08-16 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use
US9567327B2 (en) 2007-08-15 2017-02-14 Arena Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
ES2628748T3 (es) 2007-10-01 2017-08-03 Lixte Biotechnology, Inc. Inhibidores de la HDAC
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010014220A1 (en) 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
NO2364142T3 (cg-RX-API-DMAC7.html) 2008-10-28 2018-06-16
US8673920B2 (en) * 2009-05-06 2014-03-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2012058116A1 (en) 2010-10-27 2012-05-03 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2012058134A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
CN103874493A (zh) 2011-08-19 2014-06-18 默沙东公司 肾外髓质钾通道的抑制剂
EP2755656B1 (en) 2011-09-16 2016-09-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013062900A1 (en) 2011-10-25 2013-05-02 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2771005B1 (en) 2011-10-25 2016-05-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2773351B1 (en) 2011-10-31 2017-08-23 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9139585B2 (en) 2011-10-31 2015-09-22 Merck Sharp & Dohme Corp. Inhibitors of the Renal Outer Medullary Potassium channel
US9108947B2 (en) 2011-10-31 2015-08-18 Merck Sharp & Dohme Corp. Inhibitors of the Renal Outer Medullary Potassium channel
US9206199B2 (en) 2011-12-16 2015-12-08 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
JPWO2013147026A1 (ja) 2012-03-29 2015-12-14 武田薬品工業株式会社 芳香環化合物
AR092031A1 (es) 2012-07-26 2015-03-18 Merck Sharp & Dohme Inhibidores del canal de potasio medular externo renal
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9777002B2 (en) 2012-11-29 2017-10-03 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2934533B1 (en) 2012-12-19 2017-11-15 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2014126944A2 (en) 2013-02-18 2014-08-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2968288B1 (en) 2013-03-15 2018-07-04 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2014168941A1 (en) 2013-04-09 2014-10-16 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
WO2015017305A1 (en) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp Inhibitors of the renal outer medullary potassium channel
EP3063142B1 (en) 2013-10-31 2019-01-30 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
RU2696310C1 (ru) 2013-12-20 2019-08-01 Астекс Терапьютикс Лимитед Бициклические гетероциклические соединения и их применение в терапии
US10426815B2 (en) 2015-01-20 2019-10-01 The General Hospital Corporation Prevention and treatment of itch with an MRGPR antagonist
WO2016127358A1 (en) 2015-02-12 2016-08-18 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
CN109562085A (zh) 2015-06-12 2019-04-02 阿速万科学有限责任公司 用于预防和治疗rem睡眠行为障碍的二芳基和芳基杂芳基脲衍生物
KR20180064373A (ko) 2015-07-15 2018-06-14 엑소반트 사이언시즈 게엠베하 신경퇴행성 질환과 관련된 환각의 예방 및 치료에 유용한 5-ht2a 세로토닌 수용체의 조절자로서의 다이아릴 및 아릴헤테로아릴 우레아 유도체
US12168008B2 (en) 2016-12-08 2024-12-17 Lixte Biotechnology, Inc. Oxabicycloheptanes for modulation of immune response
CN119219575B (zh) * 2024-12-03 2025-03-11 天津科技大学 一种抗肿瘤肉桂基哌嗪白藜芦醇偶联物或其药学上可接受的盐及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE276541C (cg-RX-API-DMAC7.html) *
AU2859984A (en) 1983-05-23 1984-11-29 Usv Pharmaceutical Corp. Compounds for treating hypertension
US6100048A (en) 1992-04-10 2000-08-08 Oregon Health Sciences University Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
HUT78089A (hu) 1994-11-07 1999-08-30 Pfizer Inc. Neuropeptid Y1 receptorokhoz szelektíven kötődő szubsztituált piperazin-származékok
JP2000515151A (ja) 1996-07-23 2000-11-14 ニューロジェン・コーポレーション 特定の置換ベンジルアミン誘導体;新規クラスの神経ペプチド―y1特異的リガンド
ATE230403T1 (de) 1996-07-23 2003-01-15 Neurogen Corp Einige amido- und ammo- substituierte benzylaminderivate: eine neue klasse von neuropeptid y1 spezifische ligande
WO1998003494A1 (en) 1996-07-23 1998-01-29 Neurogen Corporation Certain amido- and amino-substituted benzylamine derivatives; a new class of neuropeptite y1 specific ligands
WO2000040725A1 (fr) 1998-12-28 2000-07-13 Takeda Chemical Industries, Ltd. Methode d'analyse
US6221613B1 (en) 1998-12-31 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
CA2378917A1 (en) 1999-07-14 2001-01-25 Merck & Co., Inc. Melanin-concentrating hormone receptor
AU7315800A (en) 1999-09-20 2001-04-24 Takeda Chemical Industries Ltd. Mch antagonists
CA2386474A1 (en) 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
GB0001447D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
EP1366030A2 (en) 2000-07-06 2003-12-03 Neurogen Corporation Melanin concentrating hormone receptor ligands
US6472394B1 (en) 2000-12-22 2002-10-29 Schering Corporation MCH antagonists and their use in the treatment of obesity
DE10123958A1 (de) 2001-05-17 2002-11-28 Aventis Pharma Gmbh Verfahren zur Identifizierung von Liganden für G protein coupled receptors
WO2002094799A2 (en) 2001-05-22 2002-11-28 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
US6552188B2 (en) * 2001-06-29 2003-04-22 Kowa Co., Ltd. Unsymmetrical cyclic diamine compound
DE10139416A1 (de) 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7084156B2 (en) 2001-11-27 2006-08-01 Merck & Co., Inc. 2-Aminoquinoline compounds
US6818772B2 (en) 2002-02-22 2004-11-16 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
US20040180889A1 (en) * 2002-03-01 2004-09-16 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
AU2003226927A1 (en) 2002-04-09 2003-10-27 7Tm Pharma A/S Novel carboxamide compounds for use in mch receptor related disorders
AU2003226928A1 (en) 2002-04-09 2003-10-27 7Tm Pharma A/S Novel aminotetraline compounds for use in mch receptor related disorders
US7078430B2 (en) 2002-07-08 2006-07-18 Ranbaxy Laboratories Limited HMG CoA-reductase inhibitors
FR2842524B1 (fr) 2002-07-16 2005-04-22 Aventis Pharma Sa Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-pyrrole, leur procede de preparation a titre de medicaments
US7091235B2 (en) 2002-10-15 2006-08-15 Signal Pharmaceuticals, Llc Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer

Also Published As

Publication number Publication date
JP2007502287A (ja) 2007-02-08
EP1653960A4 (en) 2008-11-26
EP1653960A2 (en) 2006-05-10
CA2533112A1 (en) 2005-03-03
AU2004266233A1 (en) 2005-03-03
WO2005019167A3 (en) 2005-12-01
US20050215526A1 (en) 2005-09-29
WO2005019167A2 (en) 2005-03-03
US20090143405A1 (en) 2009-06-04
US7514438B2 (en) 2009-04-07
US7659276B2 (en) 2010-02-09

Similar Documents

Publication Publication Date Title
MXPA06001636A (es) Antagonista del receptor de la hormona concentradora de melanina.
US7998959B2 (en) Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
US9957229B2 (en) Amido compounds and their use as pharmaceuticals
AU2002326469B2 (en) Substituted piperazines as modulators of the melanocortin receptor
MXPA06001638A (es) Antagonistas del receptor de la hormona concentradora de melanina.
AU2002319695B8 (en) Substituted piperidines as modulators of the melanocortin receptor
WO2007069053A1 (en) Benzimidazole antagonists of the h-3 receptor
JP2003513088A (ja) アリールアルカン、アリールアルケン及びアリール−アザアルカン、これら化合物を含有する製薬組成物及びその調製方法
JP2008504275A (ja) N−置換ピペリジンおよびその医薬としての使用
JP2009508963A (ja) アミド化合物および医薬組成物としてのその使用
JP2008504278A (ja) アミド化合物およびその医薬としての使用
JP7106623B2 (ja) 核内受容体に対して活性の化合物
EP1592389A2 (en) Piperazine-2-carboxamide derivatives
JP2010522156A (ja) 5−HT2c作動薬としてのピリミド[4,5−d]アゼピン誘導体
AU2006236622B2 (en) Compositions of novel opioid compounds and method of use thereof
CN115477649A (zh) 7-取代的1-芳基二氮杂萘-3-羧酰胺及其用途
WO2009001949A1 (ja) ピラゾロン誘導体
KR20230084530A (ko) 아미노이미다졸 fpr2 효능제
EA011217B1 (ru) N-[(3s)пирролидин-3-ил]бензамидные производные в качестве ингибиторов обратного захвата моноаминов
HK1141024A (en) Pyrimido [4,5-d] azepine derivatives as 5-ht2c agonists
JPWO1999055674A1 (ja) 1−[(1−置換−4−ピペリジニル)メチル]−4−ピペリジン誘導体、その製造方法、それを含有する医薬組成物および該化合物の中間体